Moderna reveals positive results from Phase 1 Covid-19 vaccine trial
Category: #health  By Saipriya Iyer  Date: 2020-07-15
  • share
  • Twitter
  • Facebook
  • LinkedIn

Moderna reveals positive results from Phase 1 Covid-19 vaccine trial

The dire need for a treatment for the coronavirus has compelled pharmaceutical companies worldwide to fast track clinical trials. U.S.-based biotech company, Moderna Inc. has recently made some developments, with its researchers claiming that their experimental COVID-19 vaccine was demonstrated to be safe and accelerated immune responses in all 45 healthy volunteers that took part in an ongoing early-stage trial.

According to credible reports, volunteers subjected to two vaccine doses reported high levels of virus-killing antibodies that surpassed average levels seen in patients that had recovered from the virus. Volunteers also didn’t experience any serious side effects, though some reported mild/moderate reactions like headache, fatigue, chills, muscle pain or aches at vaccine injected site.

Dr. Anthony Fauci, Director of NIAID (National Institute of Allergy and Infectious Diseases), praised recent developments by Moderna, adding that the study found no serious side effects and the vaccine produced relatively higher levels of virus-killing or neutralizing antibodies.

Until now, the coronavirus pandemic has impacted millions of lives and has caused nearly 575,000 deaths globally. Moderna was the first company to start human trial of its vaccine for COVID-19 in March.

With noteworthy strides made by Moderna, the US government is supporting the pharma giant’s vaccine with around half a billion dollar worth of funding and has selected its vaccine as one of the first to enter large-scale human trials.

For the uninitiated, Moderna’s mRNA-1273 uses ribonucleic acid (RNA), a chemical messenger which contains instructions for protein development. After being injected to a subject, the vaccine directs cells to make proteins that mimic the outer layer of the coronavirus, which the body identifies as a foreign object, and accelerates its immune response against it.

With pharma companies worldwide accelerating their efforts towards vaccine development, sources cite that a successful vaccine could be a significant milestone for Moderna, which has never had a licensed product.

Source Credit: https://www.hindustantimes.com/world-news/moderna-phase-1-results-show-covid-19-vaccine-safe-induces-immune-response/story-vEMNOUskkkCfSeX0yBRViI.html



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Bharat Biotech reveals positive data from animal trial of Covaxin
Bharat Biotech reveals positive data from animal trial of Covaxin
By Saipriya Iyer

Bharat Biotech, an Indian biotechnology company, has reportedly revealed positive results from the animal trial of Covaxin, India’s COVID-19 vaccine candidate.

In the animal t...

Reliance Retail sells 1.75% stake for $1.02 billion to Silver Lake
Reliance Retail sells 1.75% stake for $1.02 billion to Silver Lake
By Saipriya Iyer

Reliance Industries Ltd., an Indian conglomerate, has reportedly raised Rs.7,500 crore (Dollar 1.02 billion) by selling a stake in its retail unit to Silver Lake Partners, a private equity firm.

CNBG, Sinovac to enroll foreign patients in COVID-19 vaccine trials

CNBG, Sinovac to enroll foreign patients in COVID-19 vaccine trials
By Saipriya Iyer

The Chinese pharmaceutical firms are planning to enroll 50,000 candidates from different countries in the Phase 3 trials of COVID-19 vaccine

China National Biotec G...